
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
Coverage of the 2023 American Thoracic Society International Conference, which took place in Washington, DC.






